Greenwich Stock Story

GLSI -  USA Stock  

USD 18.14  0.40  2.16%

While many traders today are more concerned about the preservation of capital over market returns, Greenwich Lifesciences could be one exception. We will evaluate why we are still optimistic in anticipation of a recovery. In this post, I will also go over some essential variables affecting Greenwich Lifesciences' products, and show how it may impact Greenwich Lifesciences outlook for active traders this year.
Published over a month ago
View all stories for Greenwich Lifesciences | View All Stories
A comeback story in the works for Greenwich Lifesciences
The company retains a Market Volatility (i.e., Beta) of -0.4065, which attests to possible diversification benefits within a given portfolio. Let's try to break down what Greenwich's beta means in this case. As returns on the market increase, returns on owning Greenwich Lifesciences are expected to decrease at a much lower rate. During the bear market, Greenwich Lifesciences is likely to outperform the market. Even though it is essential to pay attention to Greenwich Lifesciences current price history, it is always good to be careful when utilizing equity current price movements. Our philosophy towards determining any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Greenwich Lifesciences exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Greenwich Lifesciences has an expected return of -0.39%. Please be advised to check out Greenwich Lifesciences value at risk, and the relationship between the jensen alpha and skewness to decide if Greenwich Lifesciences performance from the past will be repeated at some point in the near future.

How important is Greenwich Lifesciences's Liquidity

Greenwich Lifesciences financial leverage refers to using borrowed capital as a funding source to finance Greenwich Lifesciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Greenwich Lifesciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Greenwich Lifesciences's total debt and its cash.

How does Greenwich utilize its cash?

To perform a cash flow analysis of Greenwich Lifesciences, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Greenwich Lifesciences is receiving and how much cash it distributes out in a given period. The Greenwich Lifesciences cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Greenwich Lifesciences Net Cash Flow from Operations is most likely to decrease significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (1.04 Million)

What did Greenwich Lifesciences file with SEC?

The SEC filings are financial statements or other formal documents of Greenwich Lifesciences that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database.
Please check here for more information.
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Greenwich shareholders may or may not be submitted as SEC does not always require it.
15th of December 2021
Submission of Matters to a Vote of Security Holders
13th of December 2021
Financial Statements and Exhibits. Other Events
17th of May 2021
Other Events
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Greenwich shareholders may or may not be submitted as SEC does not always require it.

Purchase by Thompson Jaye of 500 shares of Greenwich Lifesciences

Legal trades by Greenwich Lifesciences insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Greenwich insider trading alert for perchase of common stock by Thompson Jaye, VP Clinical Reg. Affairs, on 19th of January 2022. This event was filed by Greenwich Lifesciences In with SEC on 2022-01-19. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Another Deeper Perspective

One of the ways to look at asset utilization of Greenwich is to check how much profit was generated for every dollar of assets it reports. Greenwich Lifesciences retains a negative application of resources of -9.11 (percent), losing $0.0911 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Greenwich Lifesciences shows how discouraging it operates for each dollar spent on its resources.

Over 3 percent rise for Greenwich Lifesciences. What does it mean for stockholders?

The skewness is down to 0.48 as of today. Greenwich Lifesciences exhibits very low volatility with skewness of 0.48 and kurtosis of 1.38. However, we advise investors to further study Greenwich Lifesciences technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Greenwich Lifesciences' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Greenwich Lifesciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Greenwich Lifesciences Implied Volatility

Greenwich Lifesciences' implied volatility exposes the market's sentiment of Greenwich Lifesciences stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Greenwich Lifesciences' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Greenwich Lifesciences stock will not fluctuate a lot when Greenwich Lifesciences' options are near their expiration.

Our Final Take On Greenwich Lifesciences

While many of the other players within the biotechnology industry are still a little expensive, even after the recent corrections, Greenwich Lifesciences may offer a potential longer-term growth to stockholders. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither purchase nor drop any shares of Greenwich Lifesciences at this time. The Greenwich Lifesciences risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Greenwich Lifesciences.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Greenwich Lifesciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to